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STUDY PROTOCOL
CardiOvaScular Mechanisms In Covid-19: 
methodology of a prospective observational 
multimodality imaging study (COSMIC-19 study)
Shirjel R. Alam1†, Anoop S. V. Shah2*† , Kevin O. Ombati3, Edward Nganga3, Samuel Gitau3, Khalid Makhdomi3, 
Michael H. Chung4 and Sudhir Vinayak3 
Abstract 
Background: 8–28% of patients infected with COVID-19 have evidence of cardiac injury, and this is associated with 
an adverse prognosis. The cardiovascular mechanisms of injury are poorly understood and speculative. We aim to use 
multimodality cardiac imaging including cardiac magnetic resonance (CMR) imaging, computed tomography coro-
nary angiography (CTCA) and positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-d-glucose integrated 
with computed tomography (18F-FDG-PET/CT) to identify the cardiac pathophysiological mechanisms related to 
COVID-19 infections.
Methods: This is a single-centre exploratory observational study aiming to recruit 50 patients with COVID-19 infec-
tion who will undergo cardiac biomarker sampling. Of these, 30 patients will undergo combined CTCA and 18F-FDG-
PET/CT, followed by CMR. Prevalence of obstructive and non-obstructive atherosclerotic coronary disease will be 
assessed using CTCA. CMR will be used to identify and characterise myocardial disease including presence of cardiac 
dysfunction, myocardial fibrosis, myocardial oedema and myocardial infarction. 18F-FDG-PET/CT will identify vascular 
and cardiac inflammation. Primary endpoint will be the presence of cardiovascular pathology and the association 
with troponin levels.
Discussion: The results of the study will identify the presence and modality of cardiac injury associated COVID-19 
infection, and the utility of multi-modality imaging in diagnosing such injury. This will further inform clinical decision 
making during the pandemic.
Trial Registration: This study has been retrospectively registered at the ISRCTN registry (ID ISRCTN12154994) on 14th 
August 2020. Accessible at https:// www. isrctn. com/ ISRCT N1215 4994
Keywords: COVID-19, CMR, FDG, 18F-FDG-PET/CT, CTCA , Cardiovascular, Troponin, Cardiac injury, Imaging
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Background
The number of people diagnosed with the coronavirus 
disease 2019 (COVID-19) [1] has surpassed 150 million 
worldwide claiming over 3.2 million deaths [2]. Patients 
with underlying cardiovascular comorbidity are more 
severely affected, with 8–28% of patients showing evi-
dence of heart injury [3, 4]. These patients exhibit a sub-
stantially higher death rate [5]. The odds of in-hospital 
death were 80-fold higher in patients with elevated car-
diac troponin concentrations [6].
At present, the cardiovascular pathology of injury in 
COVID-19 patients remain poorly understood, with the 
underlying mechanism being speculative [6, 7]. To date, 
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cardiac manifestations of COVID-19 infection have been 
limited to case reports and series or in patient popula-
tions who have already survived COVID-19 with imaging 
evaluating medium-term cardiac sequelea of COVID-19 
[8–10].
Using cardiac magnetic resonance (CMR) imaging [11–
13], computed tomography coronary angiogram (CTCA) 
[14] and positron emission tomography with 2-deoxy-
2-[fluorine-18]fluoro-D-glucose integrated with com-
puted tomography (18F-FDG-PET/CT) [15] during acute 
COVID-19 infection, we intend to investigate structural 
and functional changes of the myocardium and arterial 
vasculature, including evidence of inflammation, fibrosis 
and prevalence of underlying coronary atherosclerosis.
Our principal aims are to identify the cardiac patho-
physiological mechanisms related to COVID-19 infection 
that would influence care and clinical outcomes and pro-
vide insight into potential therapeutic targets.
Methods/design
This is a single-centre exploratory observational study 
involving participants diagnosed with COVID-19 receiv-
ing care at the Aga Khan University Hospital in Nai-
robi, Kenya. We aim to recruit around 50 patients with 
COVID-19 infection with 20 to 30 patients undergoing 
cardiac imaging. If feasible we will aim to image 15–20 
with plasma troponin levels, using a high-sensitivity 
assay, above the 99th centile upper reference limit (URL) 
and 5–10 patients with troponin levels within the normal 
reference range. We will additionally identify a control 
population of individuals where COVID-19 is suspected 
but excluded following testing. We will attempt to match 
controls by age and sex to the COVID-19 positive popu-
lation. All patients not requiring non-invasive and inva-
sive ventilation will be eligible for recruitment.
Selection criteria
Inclusion criteria for patients diagnosed with COVID-
19 include those over the age of 18 years, testing positive 
on PCR testing and ideally within 2  weeks of a positive 
test. Patients will be excluded based on the following 
conditions: (1) prior diagnosis of myocardial infarction, 
coronary revascularisation or cardiac surgery; (2) requir-
ing invasive or non-invasive ventilation; (3) inability to 
undergo CT or CMR scanning; (4) severe renal failure 
(estimated glomerular filtration rate < 30  mL/min); (5) 
Major allergy to iodinated contrast media/gadolinium; 
(6) pregnancy or breast feeding; (7) inability to give 
informed consent; (8) contraindication to imaging exam-
ple metal fragments in the eye. Similarly exclusion crite-
ria will apply to patients over the age of 18 years chosen 
as controls and testing negative for COVID-19.
We will also explore stratification by clinical param-
eters of COVID-19 severity. As such we will  also provide 
baseline characteritics and imaging parameters by clini-
cal requirement of oxygen supplementation.
Protection of staff and patients from COVID‑19 infection
All staff involved in scanning patients will wear personal 
protective equipment (PPE) in line with hospital policy, 
and follow protocols created by the study team includ-
ing physicians from the infectious diseases team. Patients 
will be scanned last on the list followed by a deep clean 
to the scanning area to prevent nosocomial cross infec-
tion. Routine clinical scans will be prioritised over 
research scans. No aerosol producing procedures will be 
performed.
Image acquisition
At initial recruitment, patients will undergo blood sam-
pling for high-sensitivity cardiac troponin, N-terminal 
pro B-type natriuretic peptide and high-sensitivity C 
Reactive protein. A subset of patients will be selected 
for multimodality cardiovascular imaging. These par-
ticipants will undergo two visits for a combined CTCA 
and 18F-FDG-PET/CT as soon as possible, followed by 
a CMR on another visit. All CTCA and 18F-FDG-PET/
CT will be performed within 2 weeks of presentation to 
maximise sensitivity of the scan. All efforts will be made 
to ensure CMR scans are also performed within 2 week, 
however scanning beyond this point will be performed 
if it is logistically impossible to perform the scan within 
this window.
Computed tomography coronary angiogram
CTCA scanning will be ECG-gated and performed 
in diastole during a single breath hold with prospec-
tive electrocardiographic gating, detector collimation 
64 × 0.625  mm, tube voltage 120  kV and window of 
acquisition 70–90% (or wider if necessary due to heart 
rate). Tube current will vary depending on BMI using a 
pre-specified manufacturer protocol. After the acqui-
sition of scout images, CTCA will be performed with 
iodinated contrast (Ultravist 370  mg/mL) in a biphasic 
injection protocol. Image acquisition will be triggered 
by contrast enhancement of 100 HU in the ascend-
ing aorta. In order to optimise the quality of the CTCA 
scan images, heart rate control will be pharmacologically 
achieved if appropriate, and in addition sublingual glyc-
eryl trinitrate will be administered.
18F‑FDG‑PET/CT
Participants will undergo 18F-FDG-PET/CT imag-
ing after high-fat, low-carbohydrate meal for 24  h with 
18  h fast to reduce physiologic myocardial FDG uptake 
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[15, 16]. The PET imaging will be performed 60–90 min 
after administration of 10–15  mCi of 18F-FDG using a 
GE Discovery MI series PET/CT (64 slice) scanner. The 
carotid arteries will be the superior aspect of imaging, 
and the entire thoracic aorta will be covered using 3 min 
different bed positions with additional dedicated 10 min 
cardiac acquisition. CT images will be obtained immedi-
ately after PET scan acquisition and the images co-regis-
tered following re-construction.
Cardiac magnetic resonance
Standard CMR images will be acquired as previous [17–
19]. In brief, standard pilot images and cardiac views will 
be obtained using breath-held acquisitions. Sequences 
will be as follows: (1) HASTE/White blood axial; (2) 
cines 2, 3 and 4 chamber; (3) T1 map short axis basal and 
mid-ventricular short axis slices, with additional long 
axis images if possible; (4) T2 map short axis basal and 
mid-ventricular short axis slices, with additional long 
axis images if possible; (5) post gadolinium contrast PSIR 
short axis cine stack, 2, 3 and 4 chamber; (6) post con-
trast T1 map short axis basal and mid-ventricular short 
axis slices; (7) aortic flow map.
Gadolinium-based contrast agent will be intravenously 
administered. Myocardial infarction and fibrosis will be 
identified by the presence of hyperenhancement in the 
myocardium in late enhancement images, acquired using 
a T1-inversion sequence with inversion time optimised 
on a patient-by-patient basis [20]. Multiple slices will be 
acquired in the short axis view with inversion time fur-
ther optimised for each slice. Two- and 4-chamber late 
enhancement views will also be acquired to verify pres-
ence or absence of late enhancement. Late enhancement 
images will be acquired approximately 5–12  min after 
gadolinium infusion. T1 characteristics, extra cellu-
lar volume as well as the presence of cardiac oedema by 
T2-maps will be assessed [11, 13, 21].
Image analysis
All scans will be anonymised, with analysts blinded to all 
blood results and other scanning modalities. The cardiac 
MRIs will be analysed in Manchester (UK), PET scans 
in Bristol (UK) and CTCAs in Edinburgh (UK). There 
will be no discussion regarding scans between the cen-
tres. When a second opinion is needed, it will be sought 
from an independent radiologist in Nairobi (Kenya). All 
analysis will be performed by expert cardiologists trained 
in the relevant cardiac imaging modalities. The sec-
ond opinion, when sought, will be performed by expert 
cardiothoracic radiologists.
Computed tomography coronary angiography
The presence of coronary artery disease in each major 
coronary artery, and the main side branches will be doc-
umented based on degree of stenosis. In addition pres-
ence of coronary calcification, other cardiac or vascular 
pathology, pericardial pathology and aortic/main pulmo-
nary artery diameter will be recorded.
18F‑FDG‑PET/CT
Arterial inflammation: Aortic inflammation will be 
assessed as previous [15, 22]. In brief CT and PET scan 
images will be co-registered automatically. The aorta will 
be divided into axial slices, and the tracer standardised 
uptake value (SUV) measured from a point distal to the 
origin of coronary vessels to avoid myocardial spill-over. 
Regions of interest will be drawn around the aorta in the 
axial position, repeated along the length of the aorta. A 
mean arterial SUV will be derived from the average of the 
maximum SUV values in serial axial measurements. Sim-
ilarly the average of SUV measurements from the  venous 
pool will derive the mean venous background SUV. The 
target-to-background (TBR) ratio will then be calculated 
by dividing the mean arterial SUV by the mean venous 
SUV.
Myocardial inflammation: Myocardial uptake will be 
assessed as previous [23–27]. In brief CT and PET scan 
images will be co-registered. Analysis will be performed 
on short-axis cardiac slices for later comparison with 
CMR using 17 segment model [28]. Liver SUV uptake 
will be measured by drawing a hepatic region of interest. 
Uptake in the heart as a whole will be scored according to 
a visual scale to assess cardiac suppression of FGD uptake 
(ie adequate fasting/dietary preparation).
Visual assessment of myocarditis:
A visual assessment of  FDG uptake  (on diagnos-
tic scans) that signifies myocarditis will be categorised: 
None—1, focal on diffuse—2, Focal—3, Diffuse—4.
Objective assessment of myocarditis:
Each segment of the 17 segment model, will be assessed 
for myocardial uptake visually. In addition, regions of 
interest within each myocardial segment of the 17-seg-
ment model will be drawn avoiding the blood pool and 
liver.
A mean cardiac SUV will be derived from the average 
of the maximum SUV values in serial short axis measure-
ments (Sum of each segment /17).
Assessment of each segment of the 17 segment model 
will be performed in 3 different ways as follows.
1. Raw SUV uptake compared to blood pool uptake will 
be calculated for each segment, and categorised.
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2. TBR (target-to-background-ratio) will be calculated 
by dividing each cardiac segment SUV by the mean 
blood pool SUV
3. Each segment indexed to the mean  blood pool will 
also be categorised (0—uptake < mean  blood pool 
uptake),1—uptake = mean  blood pool uptake,2—
uptake > mean  blood pool uptake but < liver uptake, 
3—(uptake > liver uptake)
Cardiac magnetic resonance imaging
Ejection fraction, regional wall motion abnormalities, 
myocardial fibrosis, oedema and presence of infarction 
will be determined as previously described [11, 13, 29]. 
Briefly, epicardial and endocardial contours will be drawn 
around diastolic phase cines, and endocardial contours 
around systolic phase cines to calculate cardiac volumes 
and myocardial mass. The myocardium will be separated 
into 16 segments of the American Heart Association 
17-segment model excluding the apex [28]. T1 values,T2 
values, extra cellular volume and the presence of late 
gadolinium enhancement will be generated for each seg-
ment using dedicated software. T1 values will indicate 
fibrosis, T2 values oedema and gadolinium enhancement 
the presence of infarction as well as fibrosis depending on 
distribution [11, 13, 20].
Primary objectives
We have four primary objectives:
• Identify the proportion of patients with biochemical 
evidence of myocardial injury or strain with the pres-
ence of elevated cardiac troponin.
• Identify significant atherosclerotic disease potentially 
causing cardiac injury with the presence of obstruc-
tive coronary artery disease on CTCA (> 50%).
• Identify myocardial disease using CMR by deter-
mining ejection fraction, presence of myocardial 
infarction (sub-endocarditis gadolinium enhance-
ment), myocarditis (mid-wall/epicardial gadolinium 
enhancement) or myocardial oedema (elevated T1 
values and T2 values)
• Identify vascular inflammation by 18F-FDG-PET/CT 
by quantifying increased FDG uptake in aorta. Deter-
mining the presence of different patterns of FDG 
uptake in myocardium will be a secondary explora-
tory outcome.
Sample size calculation and statistics
Based on published literature we based our sample size 
calculation on the assumption that 1 in 4 of hospitalised 
COVID-19 patients will have elevated cardiac troponin 
[3]. In sample size calculations, we estimated that with 
50 patients, we would be able to estimate the confidence 
interval for a prevalence of 25% with lower and upper 
intervals of 14.1% and 37.4% respectively, and that we 
would have 80% power for an alpha of 0·05 to test the 
null hypothesis that the prevalence was < 10%. This is an 
exploratory observational cross-sectional study to inves-
tigate the potential cardiac mechanisms in patients with 
COVID-19. As such we have not performed any formal 
power calculations based on imaging parameters.
Baseline clinical and imaging data will will be expressed 
as the mean ± standard deviation (SD) for parametric 
data and median (interquatile range) for non-parametric 
data. Categorical data will be presented as proportions. 
We will conduct hypothesis testing based on imaging 
parameters comparing (a) controls and patients and (b) 
within patients, those stratified by troponin concen-
trations. For within patient analysis we will attempt to 
compare individuals stratified above and below the 99th 
centile for cardiac troponin concentration. If the number 
of patients above the 99th centile for cardiac troponin are 
small, we will group patients by equal strata of cardiac 
troponin value. We will also explore stratification by clin-
ical parameters of COVID-19 severity. As such we will 
provide also provide baseline characteritics and imaging 
parameters by clinical requirement of oxygen supple-
mentation. P value of less than 0.05 will indicate statistical 
significance.
Discussion
In order to understand cardiac complications secondary 
to COVID-19, this study aims to utilise multimodality 
cardiac imaging to identify any morphological and func-
tional cardiovascular changes associated with infection. 
To date, whilst data has shown that myocardial injury is 
prevalent in patients with COVID-19, cardiac imaging 
has either been limited to case reports and small case 
series, performed after recovery using single modalities 
or using study designs highly susceptible to selection/
reporting [8–10].
To our knowledge, our study represents the first multi-
modality cardiac imaging study, with each technique 
attempting to elucidate specific pathophysiological pro-
cesses. CTCA will examine the presence of coronary dis-
ease associated directly or indirectly with elevated cardiac 
troponin concentrations, and its absence would imply 
Type 2 myocardial infarction in the correct context. CMR 
will evaluate cardiac function and dysfunction including 
structural evidence of heart failure resulting from either 
ischaemic or non-ischaemic cardiomyopathy (e.g. stress 
cardiomyopathy). It will also identify myocardial infarc-
tion or fibrosis caused by myocarditis. 18F-FDG-PET/CT 
can assess for myocardial and vascular inflammation that 
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would delineate if myocardial oedema (seen on CMR) is 
caused by direct cardiac injury or as part of a generalised 
inflammatory process.
Identification of each pathophysiological process will 
inform future studies in evaluating optimal choices of 
therapeutic agents; (1) anti-platelet and anti-coagula-
tion agents for atherosclerotic disease or thrombotic 
occlusions; (2) Blood pressure and oxygen support in 
the presence of type 2 myocardial infarction; (3) anti-
viral or anti-inflammatory strategies for a primary 
myocarditic processes; (4) early and long term cardio-
protective therapy for myocardial dysfunction.
There are several limitations and considerations that 
need to be taken into account with regards to our study 
design. First, given the imaging strategy undertaken, 
patients must be fit enough for example to breathhold. 
As such our study primarily aims to recruit COVID-19 
cases who are not requiring invasive or non-invasive 
ventilation. Our findings may therefore not be gener-
alisable to severe cases of COVID-19. Second, recent 
evidence has shown the role of anti inflammatories 
in managing patients with COVID-19. These drugs 
are likely to modulate the degree of inflammatory sig-
nal seen in the myocardium and arterial tree and may 
underestimate the true pathophysiological effect of 
the disease on the heart. Thirdly, manual selection or 
regions of interest during scan analysis is liable to error. 
This may be compounded by diminished scan quality 
due to infected patients being short of breath or tach-
ycardic. Finally, the observational trial aims to recruit 
a relatively small number of patients, and clinical out-
comes will not be evaluated. However there is a lack of 
data and well designed studies investigating COVID-19 
cardiovascular injury, and the study should provide val-
uable insights.
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